Skip to content
Clinical Trials – home
AustriaBack to Austria

Clinical trials in Mödling – page 43

863 clinical trials in Mödling, Austria. Every trial is listed in the EU Clinical Trials Register and updated daily.

Mödling at a glance
863
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

863 trials in Mödling

Open in trial search

Study of Felzartamab for Patients with Late Antibody-Mediated Rejection After Kidney Transplant

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Felzartamab
  • Sponsor:Biogen Idec Research Limited
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:GSKVx000000017064
  • Sponsor:Medical University Of Vienna

Study on the Effectiveness of Durvalumab and BCG in Treating High-Risk, Non-Muscle Invasive Bladder Cancer in Patients New to BCG Treatment

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:Durvalumab
  • Sponsor:Astrazeneca AB

Breast cancer+2

Not recruiting

Study on Denosumab to Prevent Breast Cancer in Women with BRCA1 Mutation

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · Healthy volunteers
  • Substances:Denosumab
  • Sponsor:ANZ Breast Cancer Trials Group Limited

HIV infection

Not recruiting

Study on the Safety and Effectiveness of Emtricitabine and Tenofovir Alafenamide for HIV-1 Prevention in Men and Transgender Women at Risk

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:Emtricitabine
  • Sponsor:Gilead Sciences Inc.

Splenectomy

Not recruiting

Study on the Safety and Immune Response of Meningococcal B Vaccine in Adults Without a Spleen

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · Healthy volunteers
  • Substances:Outer Membrane Vesicles (Omv) From Neisseria Meningitidis Group B Strain Nz98/254 Measured As Amount Of Total Protein Containing The Pora P1.4 Adsorbed On Aluminium Hydroxide
  • Sponsor:Medical University Of Vienna

Study Comparing Axatilimab to Best Available Therapy for Patients with Chronic Graft-Versus-Host Disease After Two or More Treatments

InvestigationalNo placebo
Countries:AustriaAustria
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Axatilimab
  • Sponsor:Incyte Corp.

Hepatitis D+1

Not recruiting

Study on Tobevibart and Elebsiran for Patients with Chronic Hepatitis D Virus Infection Not Responding to Bulevirtide Treatment

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Bulevirtide
  • Sponsor:Vir Biotechnology Inc.

Study on the Long-term Effects of Dupilumab for Patients with Aspirin-Exacerbated Respiratory Disease (AERD)

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Dupilumab
  • Sponsor:Medical University Of Vienna

Ovarian cancer

Not recruiting

Study Comparing Rinatabart Sesutecan with Other Treatments for Patients with Platinum-Resistant Ovarian Cancer

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Glatiramer Acetate
  • Sponsor:Genmab A/S

Study of M9140 for Patients with Advanced Non-Small Cell Lung Cancer

InvestigationalNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Precemtabart tocentecan
  • Sponsor:Merck Healthcare KGaA

Study of M9140 for Patients with Advanced Stomach Cancer

InvestigationalNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Precemtabart tocentecan
  • Sponsor:Merck Healthcare KGaA

Other cities in Austria

The busiest research cities in the country

All 48 cities in Austria

Clinical research in Mödling

What the registry says about research in the country

01 Diabetes & Cardiovascular Health

Clinical research focusing on Type 2 Diabetes Mellitus patients, exploring innovative approaches to prevent heart disease. The trials evaluate the effectiveness of intensive treatment using RAS-antagonists and beta-blockers compared to standard therapy.

  • Heart Disease Prevention
  • Diabetes Management
  • Cardiac Event Reduction

Studies utilize specialized biomarkers like NT-proBNP to guide treatment strategies and reduce hospitalization rates.

02 Stroke Prevention Research

Investigating advanced treatments for ischemic stroke prevention, with particular focus on patients who have experienced acute non-cardioembolic strokes or high-risk transient ischemic attacks.

  • Post-Stroke Care
  • Blood Clot Prevention
  • Antiplatelet Therapy

The research evaluates the efficacy of asundexian, an oral FXIa inhibitor, in combination with standard antiplatelet therapy.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.